Medtronic, one of the world's largest medical-device makers, is set to report its fiscal first-quarter results on Tuesday. Ahead of the release, analysts at Needham are optimistic, expecting the company to top both sales and profit expectations and possibly raise its growth outlook for fiscal 2027 as newer products gain traction.
What's driving the optimism?
Needham, an investment bank, points to Medtronic's recent momentum, led by several new product launches. Among them is Affera PFA, a heart-rhythm treatment that uses pulsed electric fields instead of heat to correct irregular heartbeats. This technology is part of a broader shift in cardiac care, as it may offer faster procedures and potentially fewer complications compared to traditional thermal ablation.
Two other products are also expected to contribute as they scale up. Symplicity Spyral is a device designed to treat high blood pressure that doesn't respond well to medication, by targeting nerves in the kidneys that can drive blood pressure up. Hugo is Medtronic's surgical robotics platform, which competes in the rapidly growing market for robot-assisted surgery.
These launches are central to the question investors are wrestling with: whether Medtronic's recent pickup is a one-time boost or a sign of durable, repeatable growth. The company has faced slower growth in some of its mature businesses, so the success of new products is key to its long-term story.
Why fiscal 2027 matters
Medtronic's fiscal year runs from late April to late April, so fiscal 2027 begins in spring 2026. When a company like Medtronic provides an outlook for a year that far out, it's a signal of management's confidence in its pipeline and market position. A higher fiscal 2027 outlook would suggest that the company sees these new products not just as short-term boosts, but as sustainable growth drivers.
For everyday investors, this is important because Medtronic is a bellwether for the medical-device industry. Its performance can influence sentiment across the sector. If Medtronic raises its long-term outlook, it could lift confidence in other device makers that are also investing in new technologies.
However, it's worth noting that fiscal 2027 is still more than a year away. Guidance that far out is often preliminary and can be revised. Investors should focus on the underlying trends—like how quickly new products are being adopted and whether they're gaining market share—rather than getting too caught up in a single number.
What to watch in the earnings report
Beyond the headline numbers, investors will be listening for details on how each of the new products is performing. For Affera PFA, the key question is how it's competing against similar devices from rivals like Boston Scientific and Johnson & Johnson. For Symplicity Spyral, the focus will be on adoption rates and reimbursement. For Hugo, the metric to watch is how many systems have been installed and how many procedures are being performed.
Medtronic's management will also likely address supply chain issues, currency fluctuations, and pricing pressure, which are common challenges for medical-device companies. Any commentary on these factors could affect the stock's reaction.
It's also worth remembering that a single earnings beat doesn't guarantee long-term success. Many companies can beat estimates for a quarter or two, but sustained growth requires consistent execution. Needham's expectation of a higher fiscal 2027 outlook is a positive sign, but it's not a certainty.
What it means for investors
For those who own Medtronic stock, the earnings report is a chance to see whether the company's growth narrative is on track. A beat and a raised outlook could provide a short-term boost to the share price. But for long-term investors, the more important takeaway is whether the company can continue to innovate and grow in a competitive market.
Medtronic operates in a sector that benefits from long-term demographic trends, like an aging population and rising rates of chronic disease. That gives the company a solid foundation. But it also faces intense competition and regulatory hurdles, so not every product launch will be a home run.
As with any earnings report, it's wise to look beyond the headline numbers and consider the quality of the results. Are sales growth and margins improving? Are the new products gaining traction? Is the company gaining or losing market share? These are the questions that will determine whether Medtronic's stock is a good long-term hold.
In the meantime, investors can also keep an eye on other companies that have recently raised their outlooks, such as Ooma's earnings beat or Abercrombie's durable growth, to gauge the broader market sentiment. But for now, all eyes are on Medtronic's Tuesday report.
